Progress reported in global fight against diarrheal disease cryptosporidiosis

May 31, 2017, Novartis Institutes for BioMedical Research

Infectious disease scientists from Novartis, the University of Georgia and Washington State University have reported the discovery and early validation of a drug candidate for treating cryptosporidiosis, a diarrheal disease which is a major cause of child mortality in lower-income countries. Currently there are no vaccines or effective treatments.

"There's a lot of uncertainty when embarking on drug discovery for a notoriously intractable parasite such as Cryptosporidium, the cause of cryptosporidiosis," said Thierry Diagana, Head of the Novartis Institute for Tropical Diseases (NITD). "Thanks to the commitment of our funding collaborators and urgent action of our academic colleagues, we've made an important step toward advancing a new treatment."

Diarrheal diseases cause more than 800,000 deaths annually[1]. Epidemiological studies have highlighted the vital need for new treatment options against the protozoan parasite Cryptosporidium, which often infects its victims from exposure to contaminated water supplies. Nitazoxanide, the only approved for cryptosporidiosis, has shown poor results in vulnerable infants and immune-compromised patients[2,3].

Yet there are obstacles to finding new treatments. The parasite perishes relatively quickly in labs and scientists have lacked research tools to identify drug candidates. The team developed a novel drug discovery process using transgenic parasites and novel models, leading to the identification and validation of the Cryptosporidium PI(4)K inhibitor candidate KDU731. They reported the discovery and preclinical findings in a recent issue of Nature.

Explore further: Team develops breakthrough tools in fight against cryptosporidium

More information: A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis, Nature (2017). nature.com/articles/doi:10.1038/nature22337

Other references:

1. Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet. 2016.

2. Amadi, B. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC infectious diseases. 2009.

3. Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. The Lancet. 2002.

Related Stories

Team develops breakthrough tools in fight against cryptosporidium

July 15, 2015
Researchers at the University of Georgia have developed new tools to study and genetically manipulate cryptosporidium, a microscopic parasite that causes the diarrheal disease cryptosporidiosis. Their discoveries, published ...

A 'tropical' parasitic disease emerges in the Canadian Arctic

April 28, 2016
An outbreak of an intestinal parasite common in the tropics, known as Cryptosporidium, has been identified for the first time in the Arctic. The discovery was made in Nunavik, Quebec, by a team from the Research Institute ...

Time to tackle cryptosporidiosis: Scientists call for crypto cure

November 13, 2013
A recent study involving more than 22,000 children in Africa and Asia revealed that the protozoan parasite Cryptosporidium is one of four pathogens responsible for the largest part of severe diarrhea in infants and toddlers.

Parasite that gives people a real bellyache during summer also found in bats

August 10, 2016
A new study from Macquarie University has found that a certain type of parasite which infects people in greater numbers during summer, causing symptoms such as diarrhoea and abdominal pain, could also be spread by bats.

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.